NCT07817251ClinicalTrials.gov
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
Safety And Tolerability of 3 Switch Regimens From Semaglutide 1.0 mg and 2.0 mg to Co-Administered Cagrilintide and Semaglutide (Cagrisema) in Participants With Type 2 Diabetes
باختصار
The purpose of this clinical study is to look at the safety and tolerability of switching from semaglutide to CagriSema, for participants who have type 2 diabetes. All participants will get CagriSema, the treatment being tested. Participants will be in…
المرحلة 3مطلوب 210 مشاركين40 موقعاًدولة واحدة
الفئات
مسجَّلة في سجل واحد
- ClinicalTrials.govNCT07817251فتح هذا السجل في ClinicalTrials.govتمت المزامنة قبل شهرين
يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.
تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.
هل أنت مهتم بهذه الدراسة؟
تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2026-09-14; recorded start 2026-09-16
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 351 other studies in this databaseCounted from the lead sponsor named in the record (Novo Nordisk A/S)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm0/15
No comparator arm stated in the record
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 40 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study: 210 participants (target), run at 40 sites.
How this score is built
- Enrolment22/40
210 participants (target)
- Site count19/25
40 sites
- Country count0/15
Single country
- Planned duration4/10
Planned over about 10 months
- Sponsor scale9/10
Novo Nordisk A/S has led 339 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
ملخص
The purpose of this clinical study is to look at the safety and tolerability of switching from semaglutide to CagriSema, for participants who have type 2 diabetes. All participants will get CagriSema, the treatment being tested. Participants will be in this clinical study for about 6 months.
الحالات
- Diabetes Mellitus, Type 2
الأهلية
| الجنس | الجميع |
|---|---|
| الأعمار | 18 Years – لا حد أقصى |
| المتطوعون الأصحّاء | لا |
الأهلية كما كُتبت في السجل
الأهلية في عبارات بسيطة
لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.
تصميم الدراسة
| نوع الدراسة | تدخّلية |
|---|---|
| المرحلة | المرحلة 3 |
| التخصيص | معشّاة |
| نموذج التدخّل | PARALLEL |
| الغرض الأساسي | TREATMENT |
| التعمية | QUADRUPLE (4) |
| التجنيد | مطلوب 210 مشاركين |
الجهة الراعية والمتعاونون
- Novo Nordisk A/S الجهة الراعية
الأذرع والتدخلات
- CagriSema dose 1EXPERIMENTAL
Participants previously treated with once-weekly semaglutide subcutaneously (s.c.) will switch to once-weekly CagriSema dose 1.
- CagriSema dose 2EXPERIMENTAL
Participants previously treated with once-weekly semaglutide s.c. will switch to once-weekly CagriSema dose 2, followed by dose 1.
- CagriSema dose 3EXPERIMENTAL
Participants previously treated with once-weekly semaglutide s.c. will switch to once-weekly CagriSema dose 3, followed by dose 2 and dose 1.
التدخلات
- دواء CagriSema
CagriSema will be administered s.c. once weekly.
مقاييس النتائج
مقياس النتيجة الأولي
Number of treatment emergent adverse events (TEAEs)
Measured as count of events.
الإطار الزمني From baseline (Week 0) to end of treatment (Week 16)
مقياس النتيجة الثانوي
Number of TEAEs
Measured as count of events.
الإطار الزمني From baseline (Week 0) to end of study (Week 22)
مقياس النتيجة الثانوي
Number of TEAEs
Measured as count of events.
الإطار الزمني From baseline (Week 0) to Week 8
مقياس النتيجة الثانوي
Number of clinically significant hypoglycaemic episodes (level 2) (less than [<] 3.0 millimoles per liter [mmol/L] (54 milligrams per deciliter [mg/dL]), confirmed by blood glucose [BG] meter)
Measured as count of episodes.
الإطار الزمني From baseline (Week 0) to end of study (Week 22)
مقياس النتيجة الثانوي
Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold
Measured as count of episodes.
الإطار الزمني From baseline (Week 0) to end of study (Week 22)
مقياس النتيجة الثانوي
Number of clinically significant hypoglycaemic episodes (level 2) (< 3.0 mmol/L (54 mg/dL), confirmed by BG meter)
Measured as count of episodes.
الإطار الزمني From baseline (Week 0) to Week 8
مقياس النتيجة الثانوي
Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold
Measured as count of episodes.
الإطار الزمني From baseline (Week 0) to Week 8
مقياس النتيجة الثانوي
Number of participants who discontinued due to gastrointestinal (GI) adverse events (AEs)
Measured as count of participants.
الإطار الزمني From baseline (Week 0) to end of treatment (Week 16)
التواريخ
| تاريخ البدء | 16 سبتمبر 2026 (فعلي) |
|---|---|
| الإتمام الأولي | 9 يونيو 2027 (تقديري) |
| الإتمام | 21 يوليو 2027 (تقديري) |
| أول نشر | 14 سبتمبر 2026 (فعلي) |
| آخر تحديث | 30 سبتمبر 2026 |
| النتائج منشورة | غير مذكور في سجل السجل |
| آخر تأكيد للحالة | سبتمبر 2026 |
فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.
المواقع
37 موقعاً قيد التجنيد
United States
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Albuquerque Clinical Trials Inc. | Albuquerque | New Mexico | قيد التجنيد |
| Amarillo Med Spec LLP | Amarillo | Texas | قيد التجنيد |
| Texas Diabetes & Endocrinology | Austin | Texas | قيد التجنيد |
| Northern Pines Hlth Ctr, PC | Buckley | Michigan | قيد التجنيد |
| North Texas Endocrine Center | Dallas | Texas | قيد التجنيد |
| Northeast Research Institute | Fleming Island | Florida | قيد التجنيد |
| Diabetes and Thyroid Center of Fort Worth | Fort Worth | Texas | قيد التجنيد |
| Ark Clinical Research | Fountain Valley | California | قيد التجنيد |
| Gilbert Center For Family Medicine | Gilbert | Arizona | قيد التجنيد |
| Thrive Clinical Research Group | Glendora | California | قيد التجنيد |
| PharmQuest Life Sciences LLC | Greensboro | North Carolina | قيد التجنيد |
| AGA Clinical Trial | Hialeah | Florida | قيد التجنيد |
| East West Med Res Inst | Honolulu | Hawaii | قيد التجنيد |
| JCCT- Juno NW Houston | Houston | Texas | قيد التجنيد |
| Sante Clinical Research | Kerrville | Texas | قيد التجنيد |
| Scripps Whittier Diabetes Inst | La Jolla | California | قيد التجنيد |
| Palm Research Center Inc-Vegas | Las Vegas | Nevada | قيد التجنيد |
| DCOL Ctr for Clin Res | Longview | Texas | قيد التجنيد |
| Downtown LA Res Ctr. Inc. | Los Angeles | California | قيد التجنيد |
| Advanced Medical Research | Maumee | Ohio | لم يبدأ التجنيد بعد |
| Adult Medicine of Lake County, Inc | Mt. Dora | Florida | قيد التجنيد |
| Clinical Research Associates | Nashville | Tennessee | قيد التجنيد |
| Tidewater Physicians Multispecialty Group | Newport News | Virginia | قيد التجنيد |
| Alliance for Multispecialty Research | Newton | Kansas | قيد التجنيد |
| North Hills Medical Research Inc | North Richland Hills | Texas | قيد التجنيد |
| Valley Clinical Trials, Inc. | Northridge | California | قيد التجنيد |
| Optimal Research Sites | Orange City | Florida | قيد التجنيد |
| Dream Team Clinical Research | Pomona | California | قيد التجنيد |
| Clinical Trials Research_Sacramento | Sacramento | California | قيد التجنيد |
| J.Lewis Research Inc | Salt Lake City | Utah | قيد التجنيد |
| NE Clin Res of San Antonio | San Antonio | Texas | لم يبدأ التجنيد بعد |
| Linda Vista Health Care Ctr | San Diego | California | قيد التجنيد |
| Diabetes & Endo Treatment Spec | Sandy City | Utah | لم يبدأ التجنيد بعد |
| Endeavor Health | Skokie | Illinois | قيد التجنيد |
| Chrysalis Clinical Research | St. George | Utah | قيد التجنيد |
| Cotton O'Neil Diabetes & Endocrinology | Topeka | Kansas | قيد التجنيد |
| Chase Medical Research LLC | Waterbury | Connecticut | قيد التجنيد |
| Iowa Diabetes & Endo Res Ctr | West Des Moines | Iowa | قيد التجنيد |
| Metabolic Research Institute Inc | West Palm Beach | Florida | قيد التجنيد |
| Accellacare Wilmington | Wilmington | North Carolina | قيد التجنيد |
مستندات الدراسة
لا تُرتبط أي مستندات في سجل السجل هذا.
التغيّرات عبر الزمن
- 30 سبتمبر 2026
تغيّرت الحالة
Status changed from Not yet recruiting to Recruiting
NOT_YET_RECRUITINGRECRUITING
- 30 سبتمبر 2026
فُتح التجنيد
Recruitment opened
NOT_YET_RECRUITINGRECRUITING